Administering ESAs to CKD patients with the goal of normalizing hemoglobin levels has not demonstrated survival or cardiovascular disease benefit, and may be harmful in comparison to a treatment regimen that delays ESA administration or sets relatively conservative targets (90–110 g/L).
Conditions: Anemia, Chronic Kidney Disease (CKD), Kidney Failure, Renal Failure
Treatments: Erythropoiesis Stimulating Agent (ESA), Erythropoietin (EPO), epoetin Alfa. Procrit, Epogen, Epoetin Beta, NeoRecormon, Darbepoetin Alfa, Aranesp, Methoxy Polyethylene Glycol-Epoetin Beta, Mircera
View PDF
Sources
- Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. Nov 16 2006;355(20):2071-2084. (PubMed)
- Moist LM, Troyanov S, White CT, et al. Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am. J. Kidney Dis. Nov 2013;62(5):860-873. (PubMed)
- Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. Nov 19 2009;361(21):2019- 2032. (PubMed)
- Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. Nov 16 2006;355(20):2085-2098. (PubMed)